Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Pharmaceutical Technology on MSN
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...
Urinary-tract infections (UTIs) are among the most common bacterial infections in humans. It is estimated that 40–50% of women will have a UTI during their lifetime 1. In addition, infection-related ...
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
Subscribe Login Register Log out My Profile Subscriber Services Search EBLADE ENTER-TO-WIN BLADE REWARDS BLADE VAULT / REPRINTS OBITUARIES JOBS CLASSIFIEDS BLADE HOMES HOMES WEEKLY ADS EVENTS CONTACT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results